Zhejiang Huahai Pharmaceutical Co., Ltd. (SHA: 600521)
China
· Delayed Price · Currency is CNY
17.93
+0.38 (2.17%)
Nov 20, 2024, 3:00 PM CST
Zhejiang Huahai Pharmaceutical Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
Net Income | 1,140 | 830.47 | 1,168 | 487.54 | 929.82 | 569.6 | Upgrade
|
Depreciation & Amortization | 767.61 | 767.61 | 672.01 | 563.07 | 470.83 | 410.66 | Upgrade
|
Other Amortization | 22.01 | 22.01 | 7.08 | 2.45 | 2.3 | 1.77 | Upgrade
|
Loss (Gain) From Sale of Assets | 0.29 | 0.29 | -3.59 | -0.6 | -19.15 | -0.02 | Upgrade
|
Asset Writedown & Restructuring Costs | 39.41 | 39.41 | 21.69 | 10.35 | 13.58 | 16.83 | Upgrade
|
Loss (Gain) From Sale of Investments | 161.97 | 161.97 | 66.48 | -442.95 | -26.09 | 17.84 | Upgrade
|
Provision & Write-off of Bad Debts | -7.93 | -7.93 | 45.37 | 14.73 | 29.6 | -10.47 | Upgrade
|
Other Operating Activities | 357.65 | 241.69 | 86.91 | 220.3 | 378.16 | 304.6 | Upgrade
|
Change in Accounts Receivable | 269.5 | 269.5 | -818.89 | -388.87 | -582.45 | 497.18 | Upgrade
|
Change in Inventory | -140.05 | -140.05 | -679.92 | -386.81 | -184.07 | -108.81 | Upgrade
|
Change in Accounts Payable | 19.99 | 19.99 | 669.89 | 679.92 | 589.22 | 18.79 | Upgrade
|
Change in Other Net Operating Assets | -0.49 | -0.49 | 81.61 | 113.74 | 5.91 | 3.52 | Upgrade
|
Operating Cash Flow | 2,643 | 2,217 | 1,243 | 938.43 | 1,555 | 1,754 | Upgrade
|
Operating Cash Flow Growth | 26.11% | 78.40% | 32.42% | -39.67% | -11.32% | 2483.29% | Upgrade
|
Capital Expenditures | -1,472 | -1,592 | -2,316 | -2,434 | -1,276 | -794.31 | Upgrade
|
Sale of Property, Plant & Equipment | 5.75 | 4.84 | 10.72 | 9.94 | 32.19 | 4.15 | Upgrade
|
Investment in Securities | -69.57 | -18.7 | -106.66 | 58.19 | -113.69 | -6.97 | Upgrade
|
Other Investing Activities | 0.4 | -16.53 | -20.35 | 9.48 | 0.44 | 6.07 | Upgrade
|
Investing Cash Flow | -1,535 | -1,623 | -2,433 | -2,357 | -1,358 | -791.06 | Upgrade
|
Long-Term Debt Issued | - | 3,321 | 3,873 | 3,238 | 6,134 | 4,268 | Upgrade
|
Total Debt Issued | 4,882 | 3,321 | 3,873 | 3,238 | 6,134 | 4,268 | Upgrade
|
Long-Term Debt Repaid | - | -3,321 | -2,732 | -1,931 | -5,135 | -4,519 | Upgrade
|
Total Debt Repaid | -4,849 | -3,321 | -2,732 | -1,931 | -5,135 | -4,519 | Upgrade
|
Net Debt Issued (Repaid) | 32.13 | -0.6 | 1,140 | 1,307 | 998.68 | -250.82 | Upgrade
|
Issuance of Common Stock | - | - | 37.68 | 371.82 | - | 970 | Upgrade
|
Repurchase of Common Stock | -71 | -71 | -172.43 | -150.01 | - | - | Upgrade
|
Common Dividends Paid | -465.12 | -556.01 | -318.32 | -387.21 | -392.83 | -208.88 | Upgrade
|
Other Financing Activities | -196.95 | -16.63 | -78.36 | -23.31 | -9.49 | -910.63 | Upgrade
|
Financing Cash Flow | -700.94 | -644.23 | 609.04 | 1,118 | 596.35 | -400.33 | Upgrade
|
Foreign Exchange Rate Adjustments | -65.06 | 29 | 54.65 | -43.49 | -85.34 | 28.69 | Upgrade
|
Net Cash Flow | 341.65 | -20.98 | -526.18 | -343.57 | 708.93 | 591.25 | Upgrade
|
Free Cash Flow | 1,171 | 624.63 | -1,074 | -1,496 | 278.97 | 959.64 | Upgrade
|
Free Cash Flow Growth | 906.01% | - | - | - | -70.93% | - | Upgrade
|
Free Cash Flow Margin | 12.53% | 7.52% | -12.99% | -22.52% | 4.30% | 17.81% | Upgrade
|
Free Cash Flow Per Share | 0.80 | 0.43 | -0.74 | -1.04 | 0.19 | 0.69 | Upgrade
|
Cash Interest Paid | 0.06 | 0.06 | 0.06 | 0.06 | - | - | Upgrade
|
Cash Income Tax Paid | 725.33 | 614.3 | 206.43 | 227.84 | 117.59 | 183.22 | Upgrade
|
Levered Free Cash Flow | 730.61 | 14.03 | -1,715 | -1,721 | -39.98 | -344.8 | Upgrade
|
Unlevered Free Cash Flow | 867.12 | 158.83 | -1,578 | -1,617 | 44.6 | -204.39 | Upgrade
|
Change in Net Working Capital | -440.76 | -112.79 | 986.12 | 109.46 | 17.32 | 343.7 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.